New DNA booster shot targets omicron variants in healthy adults

NCT ID NCT06436911

Completed ⭐️ VACCINE ⭐️ Sponsor: Entos Pharmaceuticals Inc. Source: ClinicalTrials.gov ↗

First seen Jan 04, 2026 · Last updated May 17, 2026 · Updated 17 times

Summary

This study tested a new DNA booster vaccine called Covigenix VAX-002 in 46 healthy adults aged 18 and older. The vaccine is designed to protect against newer Omicron variants of the virus that causes COVID-19. Participants had already received a primary COVID-19 vaccine or booster at least 3 months before joining. The goal was to check the vaccine's safety and how well it boosts the immune system.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID-19 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Centricity Research

Burlington, Ontario, L7M4Y1, Canada
Centricity Research

Toronto, Ontario, M4G3E8, Canada
Centricity Research

Toronto, Ontario, M9W4L6, Canada
Diex Recherche

Sherbrooke, Quebec, J1L0H8, Canada
Diex Recherche Quebec

Québec, Quebec, G1V4T3, Canada
University of Alberta

Edmonton, Alberta, Canada

Conditions

Explore the condition pages connected to this study.

COVID-19